Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the drug is a recombinant version of the human C1 inhibitor protein. Ruconest was developed by Pharming, and will be marketed by Biovitrum. The Leiden-based biotech firm will receive a EUR 5m milestone payment from its distribution partner, which will launch Ruconest initally in Germany, the UK and Scandinavia. Pharming has withdrawn its orphan drug status application in order to avoid delays in commercialising the product, which is now under development for follow-on indications.